Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a phone app and mindfulness keep chemo patients moving?

NCT ID NCT07819045

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 18, 2026 · Updated 3 times

Summary

Researchers at the University of Oklahoma are testing a mobile health program designed to help adults receiving chemotherapy for metastatic breast or gynecologic cancer stay physically active. The program combines a wearable activity tracker, behavior change techniques, acceptance and mindfulness training, and a social feature where participants share responses to weekly challenges. The study enrolls 42 people who are starting chemotherapy and measures whether the program is easy to use, useful, enjoyable, and feasible to complete.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a mobile health program combining a wearable activity tracker, acceptance and mindfulness training, and social support
What this could lead to
If it works, this approach could give people on chemotherapy a practical, phone-based way to stay active and protect their quality of life during treatment.
What could go wrong
This is a small proof-of-concept study of 42 people, so it can only show whether the program is usable and well liked, not whether it improves health. Participants may find the program hard to keep up with while managing chemotherapy side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

42 people

The number who actually took part.

Started

Sep 2025

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Having ever received a histologically confirmed diagnosis of invasive breast or gynecologic carcinoma (eligible cancer types include epithelial ovarian carcinoma, endometrial/uterine carcinoma, and invasive cervical carcinoma; other rare gynecologic malignancies \[e.g., vaginal, vulvar\] may also be included if explicitly approved by the study team) * Scheduled to receive cytotoxic chemotherapy for a minimum of 4 consecutive weeks but not yet begun or are within 4 weeks of having started their chemotherapy for cancer * Ability to speak and read English * Having internet access * Being willing and able to use a smartphone and web interface with or without assistance. If assistance is needed, it must be readily available * Adequate visual and hearing acuity to use a smartphone and web interface as indicated by self-report * Adequate motor capacity to use a smartphone and web interface as indicated by self-report * Willingness to download and use study-specific app(s), the Fitbit mobile application (this requires use of a Google Gmail account), and other mobile applications for study purposes Exclusion criteria: * Eastern Cooperative Oncology Group test score \> 2 * Having unstable bone metastases * Untreated brain metastases * Contraindications to physical activity (e.g., uncontrolled hypertension or cardiac disease) * Having a body mass index under 18 * Major psychiatric conditions such as bipolar disorder, psychosis, schizophrenia, or alcoholism that could affect the ability to understand and/or complete the study * Having arthritic or orthopedic issues that would preclude physical exercise * Another member of the household is a primary participant or staff member on this trial * Being a prisoner * Living in an assisted living facility or nursing home * Enrolled in hospice

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic invasive breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • TSET Health Promotion Research Center, Oklahoma City, Oklahoma 73104

    Oklahoma City, Oklahoma, 73104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.